Kancera AB (publ) (KAN) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.227x

Based on the latest financial reports, Kancera AB (publ) (KAN) has a cash flow conversion efficiency ratio of -0.227x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-9.80 Million ≈ $-1.05 Million USD) by net assets (Skr43.12 Million ≈ $4.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Kancera AB (publ) to measure how many days the company can operate on defensive assets alone.

Kancera AB (publ) - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how Kancera AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Kancera AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Kancera AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
ModuLink Inc. NASDAQ:MDLK	0.313x
Tianci International, Inc. Common Stock NASDAQ:CIIT	-0.369x
Astron Paper & Board Mill Limited NSE:ASTRON	0.079x
GRUPUL INDUSTRIAL ELECTROCONTACT S.A. RO:ECT	N/A
Biodexa Pharmaceticals NASDAQ:BDRX	-0.204x
EF EnergyFunders Ventures Inc V:EFV	0.007x
Fitell Corporation Ordinary Shares NASDAQ:FTEL	-0.030x
Epwin Group PLC LSE:EPWN	0.139x

Annual Cash Flow Conversion Efficiency for Kancera AB (publ) (2010–2024)

The table below shows the annual cash flow conversion efficiency of Kancera AB (publ) from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Kancera AB (publ) worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr62.30 Million ≈ $6.70 Million	Skr-58.53 Million ≈ $-6.30 Million	-0.940x	+19.56%
2023-12-31	Skr47.66 Million ≈ $5.13 Million	Skr-55.67 Million ≈ $-5.99 Million	-1.168x	-162.54%
2022-12-31	Skr106.91 Million ≈ $11.51 Million	Skr-47.56 Million ≈ $-5.12 Million	-0.445x	-23.54%
2021-12-31	Skr122.54 Million ≈ $13.19 Million	Skr-44.12 Million ≈ $-4.75 Million	-0.360x	+43.47%
2020-12-31	Skr72.28 Million ≈ $7.78 Million	Skr-46.05 Million ≈ $-4.96 Million	-0.637x	+66.66%
2019-12-31	Skr17.42 Million ≈ $1.87 Million	Skr-33.29 Million ≈ $-3.58 Million	-1.911x	-41.51%
2018-12-31	Skr33.36 Million ≈ $3.59 Million	Skr-45.04 Million ≈ $-4.85 Million	-1.350x	+2.37%
2017-12-31	Skr38.71 Million ≈ $4.17 Million	Skr-53.54 Million ≈ $-5.76 Million	-1.383x	-256.36%
2016-12-31	Skr59.52 Million ≈ $6.41 Million	Skr-23.10 Million ≈ $-2.49 Million	-0.388x	+58.81%
2015-12-31	Skr21.93 Million ≈ $2.36 Million	Skr-20.66 Million ≈ $-2.22 Million	-0.942x	-34.58%
2014-12-31	Skr27.29 Million ≈ $2.94 Million	Skr-19.11 Million ≈ $-2.06 Million	-0.700x	-99.93%
2013-12-31	Skr18.96 Million ≈ $2.04 Million	Skr-6.64 Million ≈ $-714.35K	-0.350x	+92.89%
2012-12-31	Skr5.50 Million ≈ $591.78K	Skr-27.08 Million ≈ $-2.91 Million	-4.925x	-449.52%
2011-12-31	Skr25.90 Million ≈ $2.79 Million	Skr-23.21 Million ≈ $-2.50 Million	-0.896x	-75.76%
2010-12-31	Skr11.07 Million ≈ $1.19 Million	Skr-5.64 Million ≈ $-607.38K	-0.510x	--

About Kancera AB (publ)

ST:KAN Sweden Biotechnology

Market Cap

$1.98 Million

Skr18.44 Million SEK

Market Cap Rank

#29969 Global

#694 in Sweden

Share Price

Skr0.15

Change (1 day)

-23.82%

52-Week Range

Skr0.15 - Skr1.86

All Time High

Skr38.15